Phase I clinical evaluation of anti-CD20-IFN-α to treat B-cell lymphomas (ClinicalTrials.gov Identifier NCT02519270) has been initiated and is still ongoing (Table 3). This evidence concerns the gene IFNA2 and B-cell non-Hodgkin lymphoma.